Retatrutide

Background

Retatrutide (development code LY3437943) is a synthetic, long‑acting peptide designed as a triple agonist at the glucagon-like peptide‑1 receptor (GLP‑1R), glucose‑dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR).[13] It was developed by Eli Lilly as part of a rational poly‑agonist program aimed at enhancing weight loss and metabolic control beyond that achieved with single or dual incretin agonists.[1][9][13]

Early work demonstrating synergistic metabolic benefits of combined GLP‑1, GIP, and glucagon receptor activation in preclinical models provided the conceptual basis for triagonists.[13] Retatrutide incorporates sequence engineering and fatty‑acid–based acylation to extend half‑life and permit once‑weekly subcutaneous dosing.[4][6][13] It is not an endogenous peptide and shows distinct receptor binding and signaling profiles compared with native hormones.[8][13]

Retatrutide is currently under clinical development primarily for obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‑associated steatotic liver disease (MASLD, formerly NAFLD/NASH).[6][12][14] As of the latest reports, it remains an investigational agent without marketing authorization in major jurisdictions.[9][12]

Mechanism of action

Retatrutide is a balanced but GCGR‑biased triple agonist at:

• GLP‑1 receptor (GLP‑1R)
• GIP receptor (GIPR)
• Glucagon receptor (GCGR)[8][9][13]

In recombinant cell systems, retatrutide activates all three receptors, increasing adenylate cyclase activity and intracellular cAMP.[8][13] In isolated human right atrial preparations, cumulative concentrations of 10–100 nM increased force of contraction in a concentration- and time‑dependent manner via cAMP‑dependent mechanisms, an effect attenuated by selective antagonists for GLP‑1R, GIPR, and GCGR but not by β‑adrenergic blockade.[8]

Key mechanistic components include:

• GLP‑1R agonism: Enhances glucose‑dependent insulin secretion, delays gastric emptying, suppresses appetite and food intake, and promotes weight loss.[4][6][9][13]
• GIPR agonism: Potentiates insulin secretion and may synergize with GLP‑1R activation to improve glycemic control and weight loss.[4][9][13]
• GCGR agonism: Increases energy expenditure and promotes lipid mobilization and oxidation, contributing to weight reduction but potentially counteracting insulinotropic effects; balanced co‑activation with GLP‑1R/GIPR can maintain net glucose lowering.[4][9][13][14]

In MASLD, triple agonism reduces hepatic steatosis and improves markers of liver injury, likely via weight loss–dependent and independent effects on hepatic lipid metabolism, inflammation, and fibrosis pathways.[14] Preclinical oncology models suggest retatrutide can modulate obesity‑associated tumor progression through effects on systemic metabolism and specific signaling networks (e.g., hexosamine biosynthetic pathway and YAP stability).[11][15]

Evidence summary

Phase 1b trial in T2DM

A multiple‑ascending dose, phase 1b randomized trial in adults with T2DM evaluated once‑weekly subcutaneous retatrutide versus placebo and versus dulaglutide.[4] Sample sizes were modest (tens of participants per cohort), but data indicated:

• Dose‑dependent reductions in fasting plasma glucose and HbA1c greater than dulaglutide at studied doses.
• Meaningful weight loss over the treatment period, exceeding that with dulaglutide.[4]
• Pharmacokinetics compatible with once‑weekly administration.[4]

Adverse events were mainly gastrointestinal (GI) and comparable to other incretin‑based agents.[4]

Phase 2 obesity trial (NEJM 2023)

In a pivotal phase 2, double‑blind, randomized, placebo‑controlled trial, Wilding et al. enrolled 338 adults with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with comorbidity) to receive once‑weekly retatrutide (1, 4, 8, or 12 mg with different titration schemes) or placebo for 48 weeks.[6][13]

• Primary endpoint: Percent weight change at week 24.
• 24‑week results: Least‑squares mean weight change was −7.2% (1 mg), −12.9% (combined 4 mg regimens), −17.3% (combined 8 mg), and −17.5% (12 mg), versus −1.6% with placebo.[6]
• 48‑week results: Continued weight loss with higher doses; 8 mg and 12 mg doses produced 22.8% and 24.2% mean weight reduction, respectively.[6][13][14]
• A high proportion of participants on 8–12 mg achieved ≥15% and ≥20% weight loss.[6][13]

GI events (nausea, vomiting, diarrhea) were common but mostly mild to moderate, and discontinuation rates were acceptable for a weight‑loss program.[6][12]

Phase 2a MASLD trial (Nat Med 2024)

Sanyal et al. conducted a randomized, double‑blind, placebo‑controlled phase 2a study in adults with obesity and MRI‑proton density fat fraction (MRI‑PDFF)–defined MASLD (n in the low hundreds across arms).[14]

• Primary endpoint: Mean relative change in liver fat content at week 24.
• Retatrutide (doses aligned with obesity program) achieved substantial reductions in liver fat, with a large proportion of patients attaining ≥30% relative reduction, a threshold associated with histologic improvement, alongside marked body‑weight loss.[14]
• Improvements in liver enzymes, non‑invasive fibrosis markers, and cardiometabolic risk factors were also reported.[14]

Safety findings were consistent with the obesity trial, with no major emergent hepatic safety signals over 24–48 weeks.[14]

Systematic reviews and meta‑analyses

A systematic review and meta‑analysis of randomized trials in obesity (through September 2024) reported dose‑dependent body‑weight reductions with retatrutide up to 8–12 mg once weekly, with maximal mean losses approaching 26 kg in some cohorts.[3][12]

• Retatrutide improved BMI, waist circumference, glycemic indices, and lipid parameters versus placebo and, in some studies, versus dulaglutide.[3]
• Overall adverse event risk was not significantly different from comparators (relative risk for any adverse event ~1.11, P=0.24).[12]

A narrative review of incretin triagonists highlighted retatrutide as achieving the largest mean weight loss reported to date for a pharmacologic obesity treatment in phase 2, with potential benefits across obesity‑related comorbidities including T2DM and MASLD.[1][9][13]

Preclinical and translational studies

• Cardiac physiology: In isolated human atrial tissue, retatrutide increased contractile force and shortened relaxation via cAMP‑dependent mechanisms, modulated by GLP‑1R, GIPR, and GCGR antagonists, suggesting direct cardiac effects and a potential positive inotropic profile.[8]
• Oncology/metabolism: In mouse models of obesity‑associated pancreatic cancer and triple‑negative breast cancer, retatrutide produced profound weight loss, reduced tumor engraftment and growth, and enhanced chemotherapy efficacy, possibly via modulation of the hexosamine biosynthetic pathway and YAP ubiquitylation.[11][15]
• Neurobehavioral effects: In rat alcohol discrimination paradigms, acute retatrutide administration attenuated the interoceptive effects of alcohol, paralleling semaglutide and tirzepatide, suggesting potential for repurposing in alcohol use disorder, though this remains preclinical.[7]

Clinical and research uses

Obesity and overweight

Retatrutide is under active investigation as a once‑weekly injectable treatment for obesity and overweight with weight‑related comorbidities.[6][12][13] Phase 2 data show large, sustained weight loss and improvements in multiple cardiometabolic parameters, positioning it as a potential next‑generation anti‑obesity agent pending confirmatory phase 3 trials and long‑term safety data.[6][12][13]

Type 2 diabetes mellitus

Early phase clinical data in T2DM suggest that retatrutide can lower HbA1c and body weight more than dulaglutide at tested doses, with once‑weekly dosing.[4][9] Larger, longer‑term comparative trials against standard GLP‑1R agonists and dual GLP‑1/GIP agonists (e.g., tirzepatide) are needed to define its role.[4][9]

MASLD / NASH

The phase 2a MASLD trial indicates that retatrutide has robust effects on liver fat content and metabolic parameters in patients with obesity‑associated steatotic liver disease.[14] Histologic outcomes and long‑term liver‑related endpoints remain under investigation.

Other investigational areas

Preclinical work is exploring:

• Obesity‑associated cancers (pancreatic cancer and triple‑negative breast cancer) as a metabolic adjunct to reduce tumor progression and enhance chemotherapy.[11][15]
• Alcohol use disorder, based on modulation of alcohol’s interoceptive effects in rodents.[7]
• Novel delivery systems, including oral nanoparticle formulations of retatrutide using polymerized ursodeoxycholic acid to improve peptide oral bioavailability in animal models.[10]

These applications are experimental and currently lack human efficacy data.

Dosing context

Retatrutide is administered subcutaneously once weekly in clinical trials.[4][6][12][14] Dosing regimens are investigational and should not be extrapolated to clinical practice.

• In the phase 2 obesity trial, participants received 1 mg, 4 mg (with 2 mg or 4 mg starts), 8 mg (2 mg or 4 mg starts), or 12 mg (2 mg start) once weekly for 48 weeks, with titration designed to improve tolerability.[6]
• Similar once‑weekly dose levels were used in the MASLD study, typically with gradual up‑titration to 8–12 mg over several weeks.[14]
• Phase 1b studies in T2DM used lower starting doses with stepwise escalation to evaluate safety, tolerability, and pharmacokinetics.[4]

Non‑injectable formulations, including oral nanoparticle‑based delivery, are at preclinical stages; animal studies used mg‑level doses in beagles to explore exposure profiles.[10] No approved dosing recommendations exist.

Safety profile

Common adverse effects

Across phase 1b and phase 2 trials, the most frequent adverse events are typical of incretin‑based therapies:[4][6][12]

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite

These GI events are generally mild to moderate, dose‑dependent, and more common during dose escalation; titration strategies are used to mitigate them.[6][12]

Injection‑site reactions and transient increases in heart rate, similar to other incretin agonists, have been observed but are not prominent safety signals in published reports.[6][12][13]

Serious and emerging risks

In the obesity and MASLD phase 2 programs, serious adverse events were relatively infrequent and occurred at rates similar to placebo, though numbers are small and follow‑up is limited.[6][12][14]

Potential areas of concern, based partly on class effects and mechanistic considerations, include:

• Gallbladder/biliary disease: Rapid weight loss with GLP‑1–based agents is associated with cholelithiasis and cholecystitis; retatrutide may share this risk, but specific rates are not yet well characterized.[1][9][12]
• Pancreatitis and pancreatic enzymes: Incretin agonists have been associated with pancreatitis signals; limited data for retatrutide to date do not show a clear excess, but sample sizes and duration are insufficient for firm conclusions.[4][6][12]
• Cardiovascular effects: Preclinical data show positive inotropic effects in human atrial tissue via cAMP pathways.[8] Clinical consequences (beneficial or adverse) remain uncertain, and dedicated cardiovascular outcome trials are lacking.[4][6][8][9]
• Glucose regulation in non‑diabetic individuals: GCGR activation could, in theory, predispose to hyperglycemia; in practice, GLP‑1R and GIPR activation appear to offset this, with net improvements in glycemia in obesity and MASLD trials.[6][14]

Overall, a recent meta‑analysis concluded that retatrutide’s short‑ to medium‑term safety profile in obesity is acceptable and comparable to other incretin‑based therapies, but emphasized the need for long‑term and post‑marketing data.[12]

Contraindications and precautions (class‑based context)

Formal contraindications specific to retatrutide have not been established by regulators because the drug is investigational. Based on its pharmacology and experience with GLP‑1R agonists and related agents, investigators typically exclude or exercise caution in:[4][6][9][12]

• Personal/family history of medullary thyroid carcinoma or MEN2
• History of pancreatitis
• Significant gallbladder disease
• Severe gastrointestinal motility disorders
• Advanced hepatic or renal impairment (depending on protocol)

These exclusions reflect precautionary measures rather than established contraindications for retatrutide itself.

Regulatory status

As of the latest available literature, retatrutide is an investigational medicinal product and has not been approved for clinical use in the United States, European Union, or other major regulatory regions.[1][9][12][13][14]

• Published data describe phase 1, phase 2, and early phase 2a studies; phase 3 development programs are anticipated or ongoing but results are not yet available in peer‑reviewed form.[1][6][9][12][14]
• No FDA or EMA product labels, risk‑evaluation mitigation strategies, or marketing authorizations for retatrutide were identified in current scientific and regulatory literature.[1][9][12][13]

Consequently, all clinical use of retatrutide is confined to registered clinical trials, and its future regulatory trajectory will depend on the outcomes of larger, longer‑duration efficacy and safety studies.